Sareum Holdings PLC, the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, this week announced that its application for approximately £174k grant award by UK Research & Innovation (UKRI) to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe phase Covid-19, has been conditionally approved. Subject to formal approval, Sareum has agreed to ....
